Welcome to our dedicated page for Ardent Health SEC filings (Ticker: ARDT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Ardent Health, Inc. (NYSE: ARDT) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Ardent Health is a healthcare company in the medical care facilities industry that operates 30 acute care hospitals and approximately 280 sites of care across six states, and its filings offer detailed information on its financial condition, capital structure, governance and material events.
Among the key documents available are Current Reports on Form 8-K, where Ardent Health reports significant developments. Recent 8-K filings describe quarterly financial results, including the release of earnings for specific quarters and the use of non-GAAP measures such as Adjusted EBITDA and Adjusted EBITDAR. These filings often incorporate the related earnings press release as an exhibit, providing definitions of non-GAAP metrics, reconciliations to GAAP measures and discussions of operating metrics like admissions, surgeries and net patient service revenue per adjusted admission.
Other 8-K filings detail financing and capital structure actions. For example, Ardent Health has reported amendments to its Amended and Restated Term Loan Credit Agreement and its Amended and Restated ABL Credit Agreement, extending term loan maturities, adjusting interest rate spreads over Term SOFR and the base rate, and updating baskets for certain negative covenants. Another 8-K describes the authorization of a stock repurchase program of up to $50.0 million of the company’s common stock, including the potential use of open market purchases, privately negotiated transactions, block trades and Rule 10b5-1 plans.
Filings also cover governance and executive matters, such as leadership changes and the treatment of departures under the company’s Executive Severance Plan. References to proxy statements and severance plan documents in these filings point investors to additional information on executive compensation and severance arrangements.
On Stock Titan, these ARDT filings are updated as new documents are posted to EDGAR. AI-powered summaries help explain the substance of each filing, highlight key terms in credit agreements, clarify the implications of non-GAAP metrics and stock repurchase authorizations, and make it easier to understand how individual disclosures relate to Ardent Health’s hospital operations and financial profile.
Ardent Health, Inc. director Peter J. Bulgarelli reported receiving a grant of 14,231 shares of common stock in the form of restricted stock units at no cash exercise price. Following this award, he holds 14,231 shares directly. The units vest in full on the first anniversary of April 1, 2026, conditioned on his continued service with the company through that vesting date.
Havdala Ellen reported acquisition or exercise transactions in this Form 4 filing.
Ardent Health, Inc. director Ellen Havdala reported receiving a grant of 14,231 shares of common stock in the form of restricted stock units. These units will vest in full on the first anniversary of April 1, 2026, as long as she continues serving the company through that date. After this grant, she holds 115,367 shares of common stock directly.
Sotir Mark R reported acquisition or exercise transactions in this Form 4 filing.
Ardent Health, Inc. director and Chair of the Board Mark R. Sotir received an award of 14,231 shares of Common Stock in the form of restricted stock units at no purchase price. These units vest in full on the first anniversary of April 1, 2026, contingent on his continued service with the company. Following this grant, he holds 38,709 shares directly.
Sen Rahul reported acquisition or exercise transactions in this Form 4 filing.
Ardent Health, Inc. director Rahul Sen reported an award of 14,231 shares of Common Stock in the form of restricted stock units. These units were granted at no cash cost and will vest in full on the first anniversary of April 1, 2026, contingent on his continued service. Following this compensation-related grant, Sen’s directly owned and awarded position totals 38,709 shares.
Webb Robert Thomas reported acquisition or exercise transactions in this Form 4 filing.
Ardent Health, Inc. director Robert Thomas Webb reported an equity award of 14,231 shares of Common Stock, received as a grant on April 1, 2026 at no purchase price. These represent restricted stock units that vest in full on the first anniversary of April 1, 2026, subject to his continued service. Following this award, Webb directly holds a total of 78,215 shares of Common Stock.
Robinson Edmondo reported acquisition or exercise transactions in this Form 4 filing.
Ardent Health, Inc. director Edmondo Robinson received a grant of 14,231 shares of Common Stock in the form of restricted stock units. These units vest in full on the first anniversary of April 1, 2026, if he remains in service with the company through that date. Following this award, he directly holds 58,215 shares of Common Stock.
Ardent Health, Inc. reported that director Robert DeMichiei received a grant of 14,231 restricted stock units representing its common stock. The award was granted at no cash cost and vests in full on the first anniversary of April 1, 2026, contingent on his continued service. Following this equity grant, he directly holds 24,304 shares of Ardent Health common stock. Restricted stock units are a form of share-based compensation that convert into shares when vesting conditions are met, aligning the director’s interests with long-term company performance.
GOODYEAR WILLIAM M reported acquisition or exercise transactions in this Form 4 filing.
Ardent Health, Inc. director William M. Goodyear received a grant of 14,231 shares of common stock in the form of restricted stock units at no cost. These units vest in full on the first anniversary of April 1, 2026, if he remains in service with the company. Following this award, he directly holds 115,367 shares of Ardent Health common stock.
Campion Suzanne reported acquisition or exercise transactions in this Form 4 filing.
Ardent Health, Inc. director Suzanne Campion reported receiving a grant of 14,231 shares of common stock in the form of restricted stock units. These units vest in full on the first anniversary of April 1, 2026, if she continues serving with the company through that date. After this award, she directly holds 58,215 shares of common stock, reflecting a routine equity-based compensation grant rather than an open-market purchase.
BYNOE PETER C B reported acquisition or exercise transactions in this Form 4 filing.
Ardent Health, Inc. director Peter C. B. Bynoe reported an equity award of 14,231 shares of Common Stock, received as a grant at no cash cost per share. These are restricted stock units that vest in full on the first anniversary of April 1, 2026, subject to his continued service. Following this award, he holds 115,367 shares directly.